Theramex gains €10M in licensing deal

Merck affiliate Laboratoire Theramex will pocket a €10 million licensing payment from Organon for the marketing rights to its new contraceptive EMM 310066, which has demonstrated efficacy in a Phase II trial. Theramex retains marketing rights in certain companies and also stands to garner milestones and royalties.

- read this story from AFX for more on the deal

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.